Literature DB >> 7553963

Studies on the Chinese crude drug "shoma." IX. Three novel cyclolanostanol xylosides, cimicifugosides H-1, H-2 and H-5, from cimicifuga rhizome.

M Koeda1, Y Aoki, N Sakurai, M Nagai.   

Abstract

Three new cyclolanostanol xylosides were isolated from a batch of commercial Cimicifuga Rhizome, cimicifugoside H-1 (1), C35H52O9, mp 260-262 degrees C, [alpha]D -43.5 degrees, cimicifugoside H-2 (2), C35H54O10, mp 227-229 degrees C, [alpha]D -38.8 degrees, and cimicifugoside H-5 (3), C35H52O10, mp 262-264 degrees C, [alpha]D -22.9 degrees, together with known glycosides, actein and 27-deoxyactein. Their structures were determined on the basis of chemical and spectrometric evidence including an X-ray crystallographic analysis. The structure of cimicifugoside H-1 (1) was established as (20R,24R)-24,25-epoxy-11 beta-hydroxy-3-beta-(beta-D- xylopyranosyloxy)-9,19-cyclolanost-7-ene-16,23-dione. Cimicifugoside H-5 (3) is the 15-hydroxylated derivative of 1. Since 1 changed into cimicifugoside H-2 (2) on treatment with p-toluenesulfonic acid, 2 has a 24R,25-diol structure derived from 1 by opening its epoxy ring.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7553963     DOI: 10.1248/cpb.43.771

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  3 in total

1.  Metabolic profiling of Actaea species extracts using high performance liquid chromatography coupled with electrospray ionization time-of-flight mass spectrometry.

Authors:  Chunhui Ma; Adam R Kavalier; Bei Jiang; Edward J Kennelly
Journal:  J Chromatogr A       Date:  2011-01-19       Impact factor: 4.759

2.  Differentiation of Actaea species by NMR metabolomics analysis.

Authors:  Ayano Imai; David C Lankin; Tanja Gödecke; Shao-Nong Chen; Guido F Pauli
Journal:  Fitoterapia       Date:  2020-07-15       Impact factor: 2.882

3.  Isolation of CYP3A4 Inhibitors from the Black Cohosh (Cimicifuga racemosa).

Authors:  Sachiko Tsukamoto; Maki Aburatani; Tomihisa Ohta
Journal:  Evid Based Complement Alternat Med       Date:  2005-04-20       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.